S Wergeland1, K-M Myhr2,3, K I Løken-Amsrud4, A G Beiske5, K S Bjerve6,7, H Hovdal8, R Midgard9,10, S S Kvistad11, T Holmøy12,13, T Riise14, Ø Torkildsen1,3. 1. Department of Neurology, Norwegian Multiple Sclerosis Competence Centre, Haukeland University Hospital, Bergen, Norway. 2. Department of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen, Bergen, Norway. 3. Institute of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway. 4. Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway. 5. Multiple Sclerosis Centre Hakadal, Hakadal, Norway. 6. Clinic of Laboratory Medicine, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 7. Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway. 8. Department of Neurology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 9. Department of Neurology, Molde Hospital, Molde, Norway. 10. Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway. 11. Department of Laboratory Medicine, Haukeland University Hospital, Bergen, Norway. 12. Department of Neurology, Akershus University Hospital, Lørenskog, Norway. 13. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 14. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Abstract
BACKGROUND AND PURPOSE: Our objective was to study the association between serum levels of anti Epstein-Barr virus nuclear antigen 1 (EBNA-1) antibody and 25-hydroxyvitamin D (25(OH)D) in a prospective cohort of patients with relapsing-remitting multiple sclerosis. METHOD: The study comprised 90 patients with relapsing-remitting multiple sclerosis, all participants in a randomized clinical trial of ω-3 fatty acids (the OFAMS study). Repeated, paired measurements of serum 25(OH)D and serum EBNA-1 immunoglobulin G (IgG) levels were obtained at baseline and every 6 months for 24 months. The association between serum EBNA-1 IgG and serum 25(OH)D levels was analysed using generalized linear models for hierarchical data. RESULTS: There was a significant variation in EBNA-1 IgG antibody level between sampling months (Fdf 11 = 1.8, P = 0.043, one-way anova). There was a negative association between EBNA-1 IgG and 25(OH)D [B = -0.230, 95% confidence interval (CI) (-0.440, -0.023), P = 0.030] and a positive association between EBNA-1 IgG and HLA-DRB1*15 positive status [B = 94.7, 95% CI (2.423, 186.9), P = 0.044]. The association between 25(OH)D and EBNA-1 IgG remained significant after adjusting for the patient's age, gender, HLA-DRB1*15, retinol levels and interferon β-1a treatment. CONCLUSION: Our study demonstrates monthly differences in EBNA-1 IgG levels and an association between EBNA-1 IgG, 25(OH)D levels and HLA-DRB1*15. These results indicate that EBNA-1 IgG serum levels are affected by genetic and environmental factors that also modulate multiple sclerosis risk.
RCT Entities:
BACKGROUND AND PURPOSE: Our objective was to study the association between serum levels of anti Epstein-Barr virus nuclear antigen 1 (EBNA-1) antibody and 25-hydroxyvitamin D (25(OH)D) in a prospective cohort of patients with relapsing-remitting multiple sclerosis. METHOD: The study comprised 90 patients with relapsing-remitting multiple sclerosis, all participants in a randomized clinical trial of ω-3 fatty acids (the OFAMS study). Repeated, paired measurements of serum 25(OH)D and serum EBNA-1 immunoglobulin G (IgG) levels were obtained at baseline and every 6 months for 24 months. The association between serum EBNA-1 IgG and serum 25(OH)D levels was analysed using generalized linear models for hierarchical data. RESULTS: There was a significant variation in EBNA-1 IgG antibody level between sampling months (Fdf 11 = 1.8, P = 0.043, one-way anova). There was a negative association between EBNA-1 IgG and 25(OH)D [B = -0.230, 95% confidence interval (CI) (-0.440, -0.023), P = 0.030] and a positive association between EBNA-1 IgG and HLA-DRB1*15 positive status [B = 94.7, 95% CI (2.423, 186.9), P = 0.044]. The association between 25(OH)D and EBNA-1 IgG remained significant after adjusting for the patient's age, gender, HLA-DRB1*15, retinol levels and interferon β-1a treatment. CONCLUSION: Our study demonstrates monthly differences in EBNA-1 IgG levels and an association between EBNA-1 IgG, 25(OH)D levels and HLA-DRB1*15. These results indicate that EBNA-1 IgG serum levels are affected by genetic and environmental factors that also modulate multiple sclerosis risk.
Authors: Zhi-Ming Mai; Jia-Huang Lin; Roger Kai-Cheong Ngan; Dora Lai-Wan Kwong; Wai-Tong Ng; Alice Wan-Ying Ng; Kai-Ming Ip; Yap-Hang Chan; Anne Wing-Mui Lee; Sai-Yin Ho; Maria Li Lung; Tai-Hing Lam Journal: Open Forum Infect Dis Date: 2020-09-12 Impact factor: 3.835
Authors: María Inmaculada Domínguez-Mozo; Lorena López-Lozano; Silvia Pérez-Pérez; Ángel García-Martínez; María José Torrejón; Rafael Arroyo; Roberto Álvarez-Lafuente Journal: Front Immunol Date: 2022-09-14 Impact factor: 8.786